John D. Shulman - 22 Dec 2021 Form 4 Insider Report for Petros Pharmaceuticals, Inc. (PTPI)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: PTPI
Reported as of: 22 Dec 2021
Net transaction value: +$500,001
SEC form: 4
Accepted by SEC: 03 Jan 2022, 05:13:52 UTC
Prior SEC filing: 30 Nov 2021
Next SEC filing: 29 Dec 2025
Source filing: View source filing
Reporting owner signature: [see signatures attached as Exhibit 99.2]

Key filing fact

John D. Shulman filed Form 4 for Petros Pharmaceuticals, Inc. (PTPI) on 03 Jan 2022.

Key facts

This page summarizes John D. Shulman's Form 4 filing for Petros Pharmaceuticals, Inc. (PTPI).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Jan 2022, 05:13.

Change

Previous filing in this sequence was filed on 30 Nov 2021.
Current net transaction value: +$500,001.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PTPI transaction

Common Stock, par value $0.0001 per share

Purchase

Transaction value: $500,001
Shares: +145,773
Change %: +2.6%
Price: $3.43
Shares after: 5,703,544
Date: 22 Dec 2021
Ownership: See Footnote
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PTPI transaction Derivative

Warrant

Purchase

Transaction value: $0
Shares: +109,329
Change %
Price: $0.000000
Shares after: 109,329
Date: 22 Dec 2021
Ownership: See Footnote
Underlying class: Common Stock
Underlying amount: 109,329
Exercise price: $3.50
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

See Note (1) in Exhibit 99.1.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .